THARClinical Trials•globenewswire•September 4, 2025 at 12:01 PM

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Sentiment:Neutral (60)

Summary

(NASDAQ:THAR) RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three upcoming Fall conferences.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 4, 2025 by globenewswire